Search CTL/CD8+ T-Cell Epitope Database

Found 3 matching records:

Displaying record number 56220

Download this epitope record as JSON.

HXB2 Location	Nef(72-81) DNA(9010..9039)	Nef Epitope Map
Author Location
Epitope	PQVPLRPMTY	Epitope Alignment
Subtype	C
Species (MHC/HLA)	human(B35)
Immunogen	HIV-1 infection
Country	South Africa
Experimental methods	CD8 T-cell Elispot - IFNγ, Chromium-release assay
Keywords	rate of progression

Notes

• 47 HIV-1 subtype C infected patients were followed longitudinally to determine whether there was a relation between magnitude and breadth of CTL responses in primary, acute infection (measured by IFN-gamma ELISpot) and disease progression (measured as viral load at 12 months). CTL responses to Nef were dominant (targeting 6 epitopic regions), followed by responses to Gag, Pol, Rev, Vpr, Env, Vpu, Vif and finally Tat.
• PQVPLRPMTY is a known HLA-B35-restricted epitope that is part of peptide EVGFPVRPQVPLRPMTYKA which elicited responses in 3/9 patients.

References

Gray2009 Clive M. Gray, Mandla Mlotshwa, Catherine Riou, Tiyani Mathebula, Debra de Assis Rosa, Tumelo Mashishi, Cathal Seoighe, Nobubelo Ngandu, Francois van Loggerenberg, Lynn Morris, Koleka Mlisana, Carolyn Williamson, Salim Abdool Karim, and CAPRISA 002 Acute Infection Study Team. Human Immunodeficiency Virus-Specific gamma Interferon Enzyme-Linked Immunospot Assay Responses Targeting Specific Regions of the Proteome during Primary Subtype C Infection Are Poor Predictors of the Course of Viremia and Set Point. J. Virol., 83(1):470-478, Jan 2009. PubMed ID: 18945774. Show all entries for this paper.

Displaying record number 53015

Download this epitope record as JSON.

HXB2 Location	Nef(72-81) DNA(9010..9039)	Nef Epitope Map
Author Location	Nef(72-82)
Epitope	PQVPLRPMTY	Epitope Alignment
Subtype	B
Species (MHC/HLA)	human(B35, B51)
Immunogen	HIV-1 infection
Experimental methods	CD8 T-cell Elispot - IFNγ, CD8 T-cell Elispot granzyme B
Keywords	Th1, characterizing CD8+ T cells

Notes

• Only 20% of CD8+ T-cells produce IFN-gamma and granzyme B simultaneously (Tc1a). Two additional subpopulations of HIV specific CD8 cells are found, each one constituting 30-40% of the CD8 cell pool. One of these (Tc1b) secretes IFN-gamma only, and the other one (Tc1c) secretes GzB only.
• Three of nine patients responded to this peptide with GzB producing and IFN-gamma producing cells, and one additional with IFN-gamma producing cells.

References

Kleen2004 Thomas O. Kleen, Robert Asaad, Samuel J. Landry, Bernhard O. Boehm, and Magdalena Tary-Lehmann. Tc1 Effector Diversity Shows Dissociated Expression of Granzyme B and Interferon-gamma in HIV Infection. AIDS, 18(3):383-392, 20 Feb 2004. PubMed ID: 15090789. Show all entries for this paper.

Displaying record number 58402

Download this epitope record as JSON.

HXB2 Location	Nef(72-81) DNA(9010..9039)	Nef Epitope Map
Author Location	( IIIB, MN)
Epitope	PQVPLRPMTY	Epitope Alignment
Subtype	B
Species (MHC/HLA)	human(B*51)
Immunogen	HIV-1 infection
Country	China
Experimental methods	CD8 T-cell Elispot - IFNγ, CTL suppression of replication
Keywords	rate of progression, HLA associated polymorphism, elite controllers

Notes

• To study the beneficial effects of HLA-B*51 without confounding founder effects, 22 HLA-B*51+ subjects selected from a Chinese cohort of plasma-route HIV-infected individuals, without ART for 10 years, were studied. Progression to AIDS was associated with sequential mutation selection and subsequent CTL response within 3 immunodominant epitopes, in order - Pol LPPVVAKEI (LI9), followed by Gag NANPDCKTI (NI9) and then Pol TAFTIPSI (TI8). Thus a multi-layered response is suggested to be beneficial for control in B*51-carrying controllers.
• The order of mutations in HIV-1 appears to be the L743I mutation at position 1 of the LI9 epitope followed by the V289L mutation at position 8 of TV8 epitope and then the A328S mutation in position 2 of the NI9 epitope.
• Epitope PQVPLRPMTY had a <20% frequency of recognition and a mean magnitude of ∼100 SFU/million PBMC when CTL response is measured by ex vivo EliSpot in HLA-B51+ subjects.

References

Zhang2011 YongHong Zhang, YanChun Peng, HuiPing Yan, Keyi Xu, Masumichi Saito, Hao Wu, XinYue Chen, Srinika Ranasinghe, Nozomi Kuse, Tim Powell, Yan Zhao, WeiHua Li, Xin Zhang, Xia Feng, Ning Li, Aleksandra Leligdowicz, XiaoNing Xu, Mina John, Masafumi Takiguchi, Andrew McMichael, Sarah Rowland-Jones, and Tao Dong. Multilayered Defense in HLA-B51-Associated HIV Viral Control. J. Immunol., 187(2):684-691, 15 Jul 2011. PubMed ID: 21670313. Show all entries for this paper.